文献速递乳腺癌

2022年乳腺癌统计

Breast Cancer Statistics, 2022.
PubMed 文献 · CA Cancer J Clin · 2022-10-03

本文为美国癌症协会对美国女性乳腺癌统计的更新,涵盖发病率、死亡率、生存率和乳腺X线筛查的人群数据。2010至2019年发病率每年增加0.5%,死亡率自1989年峰值后持续下降,1989至2020年总死亡率下降43%。黑人女性死亡率总体高40%,50岁以下高两倍。

要点

  • 2010至2019年乳腺癌发病率每年增加0.5%,主要由局限期和激素受体阳性疾病驱动。
  • 1989至2020年乳腺癌死亡率下降43%,相当于减少46万例死亡;2011至2020年每年下降1.3%。
  • 黑人女性乳腺癌死亡率总体比白人女性高40%,50岁以下成人高两倍。

核心结论

  • 乳腺癌死亡率自1989年峰值后持续下降,1989至2020年总死亡率下降43%,相当于减少46万例死亡。
  • 黑人女性乳腺癌死亡率总体比白人女性高40%,50岁以下成人高两倍。
  • 通过扩大高质量筛查和治疗的可及性、 nationwide Medicaid expansion 以及社区利益相关者、倡导组织和卫生系统的合作来减轻种族差异,可加速乳腺癌死亡率的改善。

研究设计与样本

  • 本文为美国癌症协会对美国女性乳腺癌统计的更新,基于人群数据描述发病率、死亡率、生存率和乳腺X线筛查情况。

主要发现

  • 2010至2019年乳腺癌发病率每年增加0.5%,主要由局限期和激素受体阳性疾病驱动。
  • 2011至2020年死亡率每年下降1.3%,而2002至2011年每年下降1.9%。
  • 1989至2020年死亡率下降43%,相当于减少46万例乳腺癌死亡。
  • 除美洲印第安人/阿拉斯加原住民外,所有种族/族裔群体的死亡率均下降,而美洲印第安人/阿拉斯加原住民的死亡率保持稳定。
  • 黑人女性发病率低于白人女性(每10万人127.8 vs 133.7),但2016至2020年死亡率总体高40%(每10万人27.6 vs 19.7),50岁以下成人高两倍(每10万人12.1 vs 6.5)。

关键数值与推荐

  • 黑人女性在每种分子亚型和疾病分期(除I期外)的5年相对生存率均为所有种族/族裔群体中最低。
  • 激素受体阳性/人表皮生长因子受体2阴性疾病的黑人-白人间绝对差距最大(88% vs 96%)。
  • 激素受体阴性/人表皮生长因子受体2阳性疾病的黑人-白人间绝对差距为(78% vs 86%)。
  • III期疾病的黑人-白人间绝对差距为(64% vs 77%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This article is the American Cancer Society's update on female breast cancer statistics in the United States, including population-based data on incidence, mortality, survival, and mammography screening. Breast cancer incidence rates have risen in most of the past four decades; during the most recent data years (2010-2019), the rate increased by 0.5% annually, largely driven by localized-stage and hormone receptor-positive disease. In contrast, breast cancer mortality rates have declined steadily since their peak in 1989, albeit at a slower pace in recent years (1.3% annually from 2011 to 2020) than in the previous decade (1.9% annually from 2002 to 2011). In total, the death rate dropped by 43% during 1989-2020, translating to 460,000 fewer breast cancer deaths during that time. The death rate declined similarly for women of all racial/ethnic groups except American Indians/Alaska Natives, among whom the rates were stable. However, despite a lower incidence rate in Black versus White women (127.8 vs. 133.7 per 100,000), the racial disparity in breast cancer mortality remained unwavering, with the death rate 40% higher in Black women overall (27.6 vs. 19.7 deaths per 100,000 in 2016-2020) and two-fold higher among adult women younger than 50 years (12.1 vs. 6.5 deaths per 100,000). Black women have the lowest 5-year relative survival of any racial/ethnic group for every molecular subtype and stage of disease (except stage I), with the largest Black-White gaps in absolute terms for hormone receptor-positive/human epidermal growth factor receptor 2-negative disease (88% vs. 96%), hormone receptor-negative/human epidermal growth factor receptor 2-positive disease (78% vs. 86%), and stage III disease (64% vs. 77%). Progress against breast cancer mortality could be accelerated by mitigating racial disparities through increased access to high-quality screening and treatment via nationwide Medicaid expansion and partnerships between community stakeholders, advocacy organizations, and health systems.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Giaquinto AN, Sung H, Miller KD, et al. Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022. PMID: 36190501. doi:10.3322/caac.21754

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。